Influencing factors for hypotension in patients undergoing double plasma molecular adsorption system artificial liver support therapy

Dongyan HU; Hong WANG; Wenyuan LI; Ling NING; Hua HAN; Qiang SHEN; Shouwei JIANG; Lei LI

doi:10.3969/j.issn.1001-5256.2022.09.024

Volume 38 Issue 9

Sep. 2022

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(9): 2078-2083

PDF( 2288 KB)

Influencing factors for hypotension in patients undergoing double plasma molecular adsorption system artificial liver support therapy

DOI: 10.3969/j.issn.1001-5256.2022.09.024

Department of Infectious Diseases, The First Affiliated Hospital of University of Science and Technology of China, Hefei 230001, China

Research funding:

Natural Science Foundation of Anhui Province (1208085QH147);

Artificial Liver Support System Special Fund Project of Beijing Hepatology Charity Foundation (RGGJJ-2021-002)

More Information

Corresponding author: JIANG Shouwei, 61747533@qq.com(ORCID: 0000-0002-3024-7368); LI Lei, lilei0403@163.com(ORCID: 0000-0002-5330-429X)
Received Date: 2022-02-04
Accepted Date: 2022-03-30
Published Date: 2022-09-20

Abstract

Abstract

Objective To investigate the risk factors for intraoperative hypotension (IOH) in patients undergoing double plasma molecular adsorption system (DPMAS) artificial liver support therapy. Methods Clinical data were collected from 181 patients (670 cases in total) who underwent DPMAS artificial liver support therapy in Liver Disease Center of The First Affiliated Hospital of University of Science and Technology of China from October 1, 2017 to December 31, 2020, and according to the presence or absence of IOH during DPMAS therapy, they were divided into IOH group with 70 patients and non-IOH group with 111 patients.Clinical indicators were compared between the two groups and their association with IOH was analyzed; prognosis was analyzed at 12 and 24 weeks.The independent samples t-test was used for comparison of normally distributed continuous data between groups, and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between groups; the chi-square test was used for comparison of categorical data between groups.Univariate and multivariate Logistic regression analyses were used to investigate the risk factors for IOH.The Kaplan-Meier method was used to plot receiver operating characteristic (ROC) curves, and the Z test was used for comparison of the area under the ROC curve (AUC) of independent risk factors. Results The univariate Logistic regression analysis showed that female individuals, individuals aged ≥50 years, and individuals with normal or low body mass index (BMI) tended to have a higher risk of IOH (all P < 0.05), and the multivariate analysis showed that normal or low BMI (odds ratio [OR]=3.290, 95% confidence interval [CI]: 1.523-7.108, P=0.002) and female sex (OR=5.146, 95% CI: 2.316-11.432, P < 0.001) were independent risk factor for IOH in patients undergoing DPMAS artificial liver support therapy.The ROC curve analysis of female sex+BMI ≤24 kg/m² showed that it had an AUC of 0.639 in predicting IOH (P=0.002).The patients experiencing IOH had a 12-week survival rate of 55.77%(29/52) and a 24-week survival rate of 50%(26/52), and there were significant differences between the two groups in 12-and 24-week survival rates (12-week: 76.53% vs 55.77%, χ²=6.887, P=0.009;24-week: 74.49% vs 50.00%, χ²=9.080, P=0.003). Conclusion The risk of hypotension was higher in female patients and that with normal or low BMI during DPMAS artificial liver therapy.Patients with IOH had poor survival prognosis at 24 weeks after DPMAS therapy.
- Liver, Artificial,
- Hypotension,
- Prognosis

FullText(HTML)

References(28)

References

[1]	PALMER BF, HENRICH WL. Recent advances in the prevention and management of intradialytic hypotension[J]. J Am Soc Nephrol, 2008, 19(1): 8-11. DOI: 10.1681/ASN.2007091006.
[2]	HU D, WU XF, TU WP. Recent advances in clinical research of intradialytic hypotension[J]. Chin Gen Prac, 2017, 20(6): 759-762. DOI: 10.3969/j.issn.1007-9572.2017.06.026. 胡丹, 吴险峰, 涂卫平. 血液透析相关性低血压的临床研究进展[J]. 中国全科医学, 2017, 20(6): 759-762. DOI: 10.3969/j.issn.1007-9572.2017.06.026.
[3]	SHEN TT, FU CZ. Effects of intraoperative hypotension on vital organ function and prognosis in patients undergoing surgery[J]. Int J Anesth Resus, 2017, 38(8): 741-746. DOI: 10.3760/cma.j.issn.1673-4378.2017.08.016. 沈通桃, 傅诚章. 术中低血压对手术患者重要器官功能和预后的影响[J]. 国际麻醉学与复苏杂志, 2017, 38(8): 741-746. DOI: 10.3760/cma.j.issn.1673-4378.2017.08.016.
[4]	NIAN SJ. Research progress on prevention of intradialysis hypotension in diabetic nephropathy patients on maintenant hemodialysis[J]. Zhejiang Med J, 2017, 39(3): 228-231. DOI: 10.3760/cma.j.issn.1673-4378.2017.08.016. 年素娟. 预防维持性血液透析糖尿病肾病患者透析中低血压的研究进展[J]. 浙江医学, 2017, 39(3): 228-231. DOI: 10.3760/cma.j.issn.1673-4378.2017.08.016.
[5]	JIAO ZF, ZHANG YM, MA XF, et al. Effects of different ultrafiltration rates on the incidence of hypotension and cardiovascular death in patients with diabetes nephropathy during maintenance hemodialysis[J]. Clin J Med Offic, 2021, 49(9): 1002-1004. DOI: 10.16680/j.1671-3826.2021.09.14. 焦占峰, 张宜明, 马小芬, 等. 不同超滤率对糖尿病肾病患者维持性血液透析中低血压及心血管死亡发生率影响[J]. 临床军医杂志, 2021, 49(9): 1002-1004. DOI: 10.16680/j.1671-3826.2021.09.14.
[6]	Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure(2018)[J]. J Clin Hepatol, 2019, 35(1): 38-44. DOI: 10.3969/j.issn.1001-5256.2019.01.007. 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版)[J]. 临床肝胆病杂志, 2019, 35(1): 38-44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.
[7]	Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association. Guideline for non-bioartificial liver support systems in treatment of liver failure: 2016 update[J]. Chin J Clin Infect Dis, 2016, 9(2): 97-103. DOI: 10.3760/cma.j.issn.1674-2397.2016.02.001. 中华医学会感染病学分会肝衰竭与人工肝学组. 非生物型人工肝治疗肝衰竭指南(2016年版)[J]. 中华临床感染病杂志, 2016, 9(2): 97-103. DOI: 10.3760/cma.j.issn.1674-2397.2016.02.001.
[8]	SANDS JJ, USVYAT LA, SULLIVAN T, et al. Intradialytic hypotension: frequency, sources of variation and correlation with clinical outcome[J]. Hemodial Int, 2014, 18(2): 415-422. DOI: 10.1111/hdi.12138.
[9]	Chinese Society of Hepatology, Chinese Medical Association. Guidelines on the management of ascites and complications in cirrhosis[J]. J Clin Hepatol, 2017, 33(10): 1847-1863. DOI: 10.3969/j.issn.1001-5256.2017.10.003. 中华医学会肝病学分会. 肝硬化腹水及相关并发症的诊疗指南[J]. 临床肝胆病杂志, 2017, 33(10): 1847-1863. DOI: 10.3969/j.issn.1001-5256.2017.10.003.
[10]	TANDON P, NEY M, IRWIN I, et al. Severe muscle depletion in patients on the liver transplant wait list: its prevalence and independent prognostic value[J]. Liver Transpl, 2012, 18(10): 1209-1216. DOI: 10.1002/lt.23495.
[11]	OBI Y, RHEE CM, MATHEW AT, et al. Residual kidney function decline and mortality in incident hemodialysis patients[J]. J Am Soc Nephrol, 2016, 27(12): 3758-3768. DOI: 10.1681/ASN.2015101142.
[12]	CHANG TI, PAIK J, GREENE T, et al. Intradialytic hypotension and vascular access thrombosis[J]. J Am Soc Nephrol, 2011, 22(8): 1526-1533. DOI: 10.1681/ASN.2010101119.
[13]	RITZ E. Left ventricular hypertrophy in renal disease: beyond preload and afterload[J]. Kidney Int, 2009, 75(8): 771-773. DOI: 10.1038/ki.2009.35.
[14]	MALIK J, LACHMANOVA J, KUDLICKA J, et al. Left atrial dysfunction in end-stage renal disease patients treated by hemodialysis[J]. Nephron, 2016, 133(3): 169-174. DOI: 10.1159/000447500.
[15]	STEFÁNSSON BV, BRUNELLI SM, CABRERA C, et al. Intradialytic hypotension and risk of cardiovascular disease[J]. Clin J Am Soc Nephrol, 2014, 9(12): 2124-2132. DOI: 10.2215/CJN.02680314.
[16]	LI YY, ZHU HD. Analysis of risk factors of intradialytic hypotension and its correlation with death[J/CD]. Chin J Front Med Sci (Electronic Version), 2019, 11(12): 106-109. DOI: 10.12037/YXQY.2019.12-15. 李媛媛, 祝浩栋. 透析中低血压的危险因素及其与患者死亡的相关性分析[J/CD]. 中国医学前沿杂志(电子版), 2019, 11(12): 106-109. DOI: 10.12037/YXQY.2019.12-15.
[17]	KUIPERS J, VERBOOM LM, IPEMA K, et al. The prevalence of intradialytic hypotension in patients on conventional hemodialysis: A systematic review with meta-analysis[J]. Am J Nephrol, 2019, 49(6): 497-506. DOI: 10.1159/000500877.
[18]	EL AMRANI M, EL KABBAJ D. Isolated diastolic hypotension in hemodialysis: Risk factor for novel cardiovascular complications and all-cause mortality[J]. Ann Cardiol Angeiol (Paris), 2019, 68(3): 144-149. DOI: 10.1016/j.ancard.2018.09.010.
[19]	HALLE MP, HILAIRE D, FRANCOIS KF, et al. Intradialytic hypotension and associated factors among patients on maintenance hemodialysis: A single-center study in cameroon[J]. Saudi J Kidney Dis Transpl, 2020, 31(1): 215-223. DOI: 10.4103/1319-2442.279944.
[20]	LI Y, WRIGHT MD. Patient positioning during a hypotensive episode for adults undergoing hemodialysis: A review of clinical effectiveness and guidelines[M]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health, 2020.
[21]	WANG Y, JIANG Y, ZHANG M, et al. Prevalence and relevant factors of adult hypoteusion in China[J]. Pract Prev Med, 2009, 16(1): 49-51. DOI: 10.3969/j.issn.1006-3110.2009.01.016. 汪媛, 姜勇, 张梅, 等. 中国成人低血压患病率及其相关因素[J]. 实用预防医学, 2009, 16(1): 49-51. DOI: 10.3969/j.issn.1006-3110.2009.01.016.
[22]	LIU X, WANG XF, ZHANG T, et al. Clinical analysis of hypotension during hemodialysis[J]. Chin J Blood Purif, 2021, 20(1): 50-53. DOI: 10.3969/j.issn.1671-4091.2021.01.12. 刘寻, 王晓菲, 张婷, 等. 血液透析中低血压临床分析[J]. 中国血液净化, 2021, 20(1): 50-53. DOI: 10.3969/j.issn.1671-4091.2021.01.12.
[23]	TIAN M, ZHA Y, QIE S, et al. Association of body composition and intradialytic hypotension in hemodialysis patients[J]. Blood Purif, 2020, 49(3): 334-340. DOI: 10.1159/000504245.
[24]	LAUTH M, BERNAL W, DASARATHY S, et al. ESPEN guide-line on clinical nutrition in liver disease[J]. Clin Nutr, 2019, 38(2): 485-521. DOI: 10.1016/j.clnu.2018.12.022.
[25]	Chinese Society of Hepatology, Chinese society of Gastroenterology, Chinese Medical Association. Clinical guidelines on nutrition in end-stage liver disease[J]. J Clin Hepatol, 2019, 35(6): 1222-1230. DOI: 10.3969/j.issn.1001-5256.2019.06.010. 中华医学会肝病学分会, 中华医学会消化病学分会. 终末期肝病临床营养指南[J]. 临床肝胆病杂志, 2019, 35(6): 1222-1230. DOI: 10.3969/j.issn.1001-5256.2019.06.010.
[26]	EBADI M, BHANJI RA, DUNICHAND-HOEDL AR, et al. Sarcopenia severity based on computed tomography image analysis in patients with cirrhosis[J]. Nutrients, 2020, 12(11): 3463. DOI: 10.3390/nu12113463.
[27]	GENG N, KONG M, CHEN Y, et al. Value of L3 skeletal muscle index in nutritional diagnosis of end-stage liver disease[J]. J Clin Hepatol, 2021, 37(10): 2493-2496. DOI: 10.3969/j.issn.1001-5256.2021.10.050. 耿楠, 孔明, 陈煜, 等. 第三腰椎骨骼肌指数在终末期肝病营养诊断中的应用价值[J]. 临床肝胆病杂志, 2021, 37(10): 2493-2496. DOI: 10.3969/j.issn.1001-5256.2021.10.050.
[28]	XU M, LI T, KONG M, et al. Psoas muscle index can be used to predict long-term mortality in young male patients with acute-on-chronic liver failure[J]. Front Nutr, 2022, 9: 811826. DOI: 10.3389/fnut.2022.811826.

Relative Articles

[1]	Zhiying LIU, Zhihang ZHOU, Song HE. Research advances in the role of blood metabolic markers in the treatment response and prognosis prediction of primary liver cancer[J]. Journal of Clinical Hepatology, 2023, 39(10): 2470-2475. doi: 10.3969/j.issn.1001-5256.2023.10.028
[2]	Ying TU, Xue LI, Meijuan CHEN, Huaqian XU, Shanhong TANG. Value of platelet count and related scoring models in predicting the prognosis of hepatitis B virus-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2023, 39(6): 1308-1312. doi: 10.3969/j.issn.1001-5256.2023.06.009
[3]	Sufang LU, Rui HUANG, Hongli ZHAO, Dandan WANG, Yuzhen DING, Hong ZHOU. Value of a risk assessment model in predicting venous thromboembolism in patients with liver failure after artificial liver support therapy[J]. Journal of Clinical Hepatology, 2023, 39(3): 613-619. doi: 10.3969/j.issn.1001-5256.2023.03.019
[4]	Ying LIU, Ping ZHU, Jing LIANG, Huiling XIANG. Value of total bilirubin rebound rate and total bilirubin clearance rate in evaluating the prognosis of severe drug-induced liver injury after artificial liver support therapy[J]. Journal of Clinical Hepatology, 2023, 39(3): 606-612. doi: 10.3969/j.issn.1001-5256.2023.03.018
[5]	Wanshu LIU, Lijun SHEN, Qinghui ZHAI, Shaojie XIN, Shaoli YOU. Risk factors for acute variceal bleeding in acute-on-chronic liver failure and its influence on prognosis[J]. Journal of Clinical Hepatology, 2022, 38(11): 2532-2536. doi: 10.3969/j.issn.1001-5256.2022.11.018
[6]	Jie LU, Dingchun LI, Ye LIU, Linna YUAN, Zhiwen DUAN, Wu LI. Clinical efficacy of low-dose plasma exchange combined with double plasma molecular absorption system/hemoperfusion in treatment of acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2022, 38(11): 2526-2531. doi: 10.3969/j.issn.1001-5256.2022.11.017
[7]	Lu WANG, Wenxiong XU, Shu ZHU, Xuejun LI, Yuanli CHEN, Chan XIE, Liang PENG. Influence of artificial liver support system therapy on platelet in treatment of hepatitis B virus-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2022, 38(5): 1053-1058. doi: 10.3969/j.issn.1001-5256.2022.05.015
[8]	Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Expert consensus on clinical application of artificial liver and blood purification (2022 edition)[J]. Journal of Clinical Hepatology, 2022, 38(4): 767-775. doi: 10.3969/j.issn.1001-5256.2022.04.007
[9]	Yuyu ZENG, Dakai GAN, Nengwen XIE, Jiao WAN, Molong XIONG. Prognosis and adverse reactions of patients with acute-on-chronic liver failure receiving artificial liver support therapy stratified by international normalized ratio[J]. Journal of Clinical Hepatology, 2022, 38(10): 2308-2312. doi: 10.3969/j.issn.1001-5256.2022.10.020
[10]	Bin WANG, Hansheng LIANG, Yi FENG, Youzhong AN. Risk factors for perioperative hypotension in severe patients after liver cancer surgery[J]. Journal of Clinical Hepatology, 2022, 38(3): 572-576. doi: 10.3969/j.issn.1001-5256.2022.03.015
[11]	Beibei HUANG, Ling NING, Wenyuan LI, Xiaowei ZHENG, Yue ZHANG, Shouwei JIANG, Zhenhua ZHANG, Lei LI. Establishment of a predictive model for the prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure treated with plasma exchange and double plasma molecular adsorption system alone or in combination[J]. Journal of Clinical Hepatology, 2021, 37(12): 2802-2807. doi: 10.3969/j.issn.1001-5256.2021.12.015
[12]	Xu Ying, Huang XiaoPing, Chen Li, Gu Jing, Wang Yan, Gan JianHe. Value of mean platelet volume in evaluating the prognosis of hepatitis B virus-associated acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2020, 36(10): 2199-2202. doi: 10.3969/j.issn.1001-5256.2020.10.008
[13]	Wang ZhiXin, Li Yao, Zhou LiuXin, Ren Li, Qu Kai, Miao Run, Hou LiChao, Wang HaiJiu, Liu Chang, Fan HaiNing. Influence of 5-hydroxytryptamine and platelet count in peripheral blood on the prognosis of patients with hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(7): 1534-1539. doi: 10.3969/j.issn.1001-5256.2020.07.017
[14]	LI Hui, WANG YongGang, SU HaiBin. Application of blood lactate level in evaluating the prognosis of liver failure patients[J]. Journal of Clinical Hepatology, 2020, 36(11): 2609-2612. doi: 10.3969/j.issn.1001-5256.2020.11.048
[15]	Ye YingJian, Liu Bo, Chen Wei, Li QiongXia. Prognosis and staging system analysis of hepatocellular carcinoma patients with negative serum alpha-fetoprotein[J]. Journal of Clinical Hepatology, 2019, 35(3): 535-541. doi: 10.3969/j.issn.1001-5256.2019.03.017
[16]	Tong JingJing, Mu XiuYing, Xu Xiang, Chen Jing, Zhai XingRan, Wang Yu, Su HaiBin, Liu XiaoYan, Hu JinHua. Association between blood ammonia and 90-day prognosis in patients with hepatitis B virus-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2019, 35(6): 1304-1307. doi: 10.3969/j.issn.1001-5256.2019.06.024
[17]	Deng WeiWei, Zhu WenMing, Yi Chao, Feng YangChun, Huang YanChun. Association of serum interleukin-17 level with early recurrence and prognosis after radical surgery in hepatocellular carcinoma patients with different levels of alpha-fetoprotein[J]. Journal of Clinical Hepatology, 2018, 34(2): 298-302. doi: 10.3969/j.issn.1001-5256.2018.02.016
[18]	Tang Wen, Wang Yu, Zhao XinYan, Wang XiaoMing, Ou XiaoJuan, Jia JiDong. Impact of portal vein thrombosis on prognosis of patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2017, 33(3): 466-471. doi: 10.3969/j.issn.1001-5256.2017.03.014
[19]	Li Ying, Xu JiZhe, Liang LiNa, Liu LiNa. Relationship of hyponatremia with degree of liver injury and prognosis in patients with decompensated liver cirrhosis[J]. Journal of Clinical Hepatology, 2016, 32(3): 499-502. doi: 10.3969/j.issn.1001-5256.2016.03.021

Supplements(0)

Cited By

Cited by

Periodical cited type(3)

1.	仲秀利，崔文静，许燕. 血浆置换治疗肝衰竭后发生不良反应的影响因素分析及列线图预测模型的建立. 中国肝脏病杂志(电子版). 2024(01): 52-56 .
2.	周圣瑜，张凌，杨莹莹，陈志文，强靖雅，赵媛. 双重血浆分子吸附系统不同治疗时间的有效性与安全性研究. 中国血液净化. 2024(09): 655-658 .
3.	中国肝炎防治基金会，双重血浆分子吸附系统临床应用及操作技术规范专家组. 双重血浆分子吸附系统的临床应用及操作技术规范. 中华肝脏病杂志. 2024(12): 1073-1085 .

Other cited types(1)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(2) / Tables(3)

Get Citation

PDF

XML

Article Metrics

Article views (533) PDF downloads(39)

Influencing factors for hypotension in patients undergoing double plasma molecular adsorption system artificial liver support therapy

DOI: 10.3969/j.issn.1001-5256.2022.09.024